BioAge Labs vs Genentech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage biotech targeting metabolic aging for obesity and muscle-wasting disorders. IPO Sep 2024 (Nasdaq: BIOA); $198M raised; lead program azelaprag discontinued; pivoting to NLRP3 inhibitors.
About
BioAge Labs is a clinical-stage biopharmaceutical company that harnesses the biology of human aging to discover novel targets and therapies for metabolic diseases. The company went public on the Nasdaq Global Select Market in September 2024 under the ticker BIOA, raising $198M. Its lead program, azelaprag — an oral APJ agonist — was discontinued in January 2025 after the Phase 2 STRIDES obesity trial observed liver transaminitis in a subset of patients. BioAge has since pivoted its APJ program to next-generation oral and parenteral agonists targeting 2026 IND submissions, while advancing BGE-102, a brain-penetrant NLRP3 inhibitor development candidate with potential best-in-class CNS and metabolic applications. The company continues to leverage its proprietary human aging database to identify and validate novel drug targets.
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.